Comparative Pharmacology
Head-to-head clinical analysis: DURANEST versus XYLOCAINE 1 5 W DEXTROSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURANEST versus XYLOCAINE 1 5 W DEXTROSE 7 5.
DURANEST vs XYLOCAINE 1.5% W/ DEXTROSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
Lidocaine is an amide-type local anesthetic that blocks sodium channels, thereby inhibiting the propagation of action potentials in peripheral nerves, leading to local anesthesia.
2-10 mL of a 1-2% solution, subarachnoid injection, single dose only.
Spinal anesthesia: 1.5-2 mL (22.5-30 mg lidocaine) for lower extremity or perineal procedures; 2-3 mL (30-45 mg) for lower abdominal or urological procedures. Administered via lumbar puncture.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
Terminal elimination half-life: 1.5–2 hours in adults with normal hepatic function; may be prolonged to 3–5 hours in patients with hepatic impairment or congestive heart failure.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and conjugates) accounts for >80% of elimination; less than 10% eliminated unchanged in urine. Biliary/fecal excretion of metabolites contributes <10%.
Category C
Category C
Local Anesthetic
Local Anesthetic